
https://www.science.org/content/blog-post/countries-have-developed-small-molecule-drug
# Countries That Have Developed A Small-Molecule Drug (April 2015)

## 1. SUMMARY

This blog post from 2015 posed a straightforward question: "how many countries really have developed a small-molecule drug with their own resources?" The author adopted a "medium-generous" definition that allowed counting drugs where substantial development work occurred in a country, even if the original target discovery happened elsewhere. The post explicitly excluded vaccines, phages, and biologics. Initially listing US, Canada, UK, Germany, Switzerland, France, Netherlands, Belgium, Denmark, Sweden, Italy, Russia, Japan, and China, the author acknowledged gaps and invited reader feedback. Through updates, the list expanded to 24 countries including Spain, Portugal, Finland, Norway, Poland, Hungary, former Czechoslovakia, Austria, Israel, India, South Korea, and Australia.

## 2. HISTORY

The article's question reflects the early 2010s landscape when analyzing geographic distribution of drug development was gaining attention. In the decade following 2015, several trends emerged:

**Clinical development patterns**: Clinical trial site distributions have shown continued concentration in North America and Europe, though with gradual expansion into Asia-Pacific and Latin America. Many countries on the 2015 list remain dominant in trial recruitment and drug development.

**Regulatory harmonization**: Countries like Switzerland, Sweden, Denmark, and the Netherlands have maintained strong pharmaceutical industries, while regulatory frameworks have become more standardized across the European Union.

**China's expansion**: The 2015 mention of China preceded dramatic growth in Chinese biopharmaceutical capabilities. Since then, China has substantially increased both R&D investment and the number of domestic drug approvals.

**Production geography**: Actual drug manufacturing capacity remains concentrated in specific countries regardless of original discovery location, with supply chain considerations becoming more prominent in global health discussions.

## 3. PREDICTIONS

The post asked whether additional countries deserved inclusion, implicitly predicting readers would expand the list. Several observations from the following years:

- The updated list proved reasonably comprehensive for 2015 capabilities
- Small countries like Denmark, Sweden, and the Netherlands have maintained pharmaceutical presence, often specializing in specific therapeutic areas
- Some countries (Spain, Italy) have pharmaceutical industries but face challenges in translating research into nationally-developed proprietary drugs
- The definition challenge remains: distinguishing between multinational company presence versus genuine domestic capability

## 4. INTEREST

Rating: **7/10**

The post highlighted a real geographic asymmetry in pharmaceutical innovation capabilities, making it a concrete discussion of global research distribution. While not groundbreaking methodology, it addressed an important topic with some staying power.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20150407-countries-have-developed-small-molecule-drug.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_